Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW.

J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29. Review.

2.

Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.

Ashbee HR, Gilleece MH.

Bone Marrow Transplant. 2012 Jul;47(7):881-94. doi: 10.1038/bmt.2011.146. Epub 2011 Jul 25. Review.

PMID:
21785468
3.

Prevalence and management of non-albicans vaginal candidiasis.

Hettiarachchi N, Ashbee HR, Wilson JD.

Sex Transm Infect. 2010 Apr;86(2):99-100. doi: 10.1136/sti.2009.040386. Erratum in: Sex Transm Infect. 2010 Jun;86(3):250. Hetticarachchi, Nalin [corrected to Hettiarachchi, Nalin].

PMID:
20332368
4.

Histoplasmosis in Europe: report on an epidemiological survey from the European Confederation of Medical Mycology Working Group.

Ashbee HR, Evans EG, Viviani MA, Dupont B, Chryssanthou E, Surmont I, Tomsikova A, Vachkov P, Enero B, Zala J, Tintelnot K; ECMM Working Group on; Histoplasmosis.

Med Mycol. 2008 Feb;46(1):57-65.

PMID:
17885939
5.

Update on the genus Malassezia.

Ashbee HR.

Med Mycol. 2007 Jun;45(4):287-303. Review.

PMID:
17510854
6.

Recent developments in the immunology and biology of Malassezia species.

Ashbee HR.

FEMS Immunol Med Microbiol. 2006 Jun;47(1):14-23. Review.

7.

Testing of antifungal combinations against yeasts and dermatophytes.

Harman S, Ashbee HR, Evans EG.

J Dermatolog Treat. 2004 Apr;15(2):104-7.

PMID:
15204161
8.

Skin colonization by Malassezia in neonates and infants.

Ashbee HR, Leck AK, Puntis JW, Parsons WJ, Evans EG.

Infect Control Hosp Epidemiol. 2002 Apr;23(4):212-6.

PMID:
12002236
9.

Production of the mycelial phase of Malassezia in vitro.

Saadatzadeh MR, Ashbee HR, Holland KT, Ingham E.

Med Mycol. 2001 Dec;39(6):487-93.

PMID:
11798054
10.

Immunology of diseases associated with Malassezia species.

Ashbee HR, Evans EG.

Clin Microbiol Rev. 2002 Jan;15(1):21-57. Review.

11.

A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion.

Liebowitz LD, Ashbee HR, Evans EG, Chong Y, Mallatova N, Zaidi M, Gibbs D; Global Antifungal Surveillance Group.

Diagn Microbiol Infect Dis. 2001 May-Jun;40(1-2):27-33.

PMID:
11448560
12.

An investigation into the pathogenesis of vulvo-vaginal candidosis.

El-Din SS, Reynolds MT, Ashbee HR, Barton RC, Evans EG.

Sex Transm Infect. 2001 Jun;77(3):179-83.

13.

Vaginal yeasts in the era of "over the counter" antifungals.

Walker PP, Reynolds MT, Ashbee HR, Brown C, Evans EG.

Sex Transm Infect. 2000 Dec;76(6):437-8.

14.

Cell-mediated immunity to the mycelial phase of Malassezia spp. in patients with pityriasis versicolor and controls.

Saadatzadeh MR, Ashbee HR, Cunliffe WJ, Ingham E.

Br J Dermatol. 2001 Jan;144(1):77-84.

PMID:
11167686
15.

The role of Malassezia species in the ecology of human skin and as pathogens.

Guého E, Boekhout T, Ashbee HR, Guillot J, Van Belkum A, Faergemann J.

Med Mycol. 1998;36 Suppl 1:220-9. Review.

PMID:
9988511
16.

IgG subclasses specific to Staphylococcus epidermidis and Propionibacterium acnes in patients with acne vulgaris.

Ashbee HR, Muir SR, Cunliffe WJ, Ingham E.

Br J Dermatol. 1997 May;136(5):730-3.

PMID:
9205507
17.

Humoral immunity to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls.

Ashbee HR, Fruin A, Holland KT, Cunliffe WJ, Ingham E.

Exp Dermatol. 1994 Oct;3(5):227-33.

PMID:
7881768
18.
19.

The carriage of Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls.

Ashbee HR, Ingham E, Holland KT, Cunliffe WJ.

Br J Dermatol. 1993 Nov;129(5):533-40.

PMID:
8251348

Supplemental Content

Loading ...
Support Center